Future of Cell Therapy in the Regenerative Medicine Market

  • ID: 3754121
  • Report
  • Region: Global
  • 107 Pages
  • Frost & Sullivan
1 of 3
Combination Therapies and Advanced Manufacturing Techniques are the New Criteria Shaping the $4 Billion Market
Research Overview

This research analyses the current trends, forecasts and the external factors influencing the global cell therapy market. It also studies top participants in the market, disruptive pipeline products, and the opportunities in combination therapy. In addition, it provides a detailed commercialization analysis of research and development (R&D), manufacturing, and funding considerations.

In this research, expert analysts thoroughly examine the following market segments:

- Cell-based immunotherapy
- Stem cell therapy
- Cell-gene therapy
- Stem cell-gene therapy

They also analyze the following geographic segments in detail:

- North America (Canada, the United States of America)
- Europe (Germany, United Kingdom, Benelux, Spain, France, Scandinavia, Italy)
- Asia-Pacific (Japan, Association of South East Asian Nations (ASEAN), China, India)
- Rest of the world (Brazil, Africa, Russia)

Market Overview

Late Stage Hybrid Cell Therapy to Disrupt the Overall Cell Therapy Market

Heavy investments in the development and commercialization of cell therapy products have made North America the forerunner with 50 percent share in the global cell therapy market. However, the Asia-Pacific market is growing at a faster rate, on the strength of the intensified R&D activity in Japan and South Korea. Meanwhile, the pressure to reduce the cost of care for aging population has driven the governments in some countries including, Japan, Canada, and the United States to create programs to facilitate the rapid commercialization of therapy products.

Accordingly, the United States and Japan have fast tracked R&D in treatments that employ highly curative stem cell, cell-gene, and immunotherapy. Many governments in North America and the Asia-Pacific are drafting policies to encourage the establishment of centers of excellence, manufacturing infrastructure and research networks to ensure profitable commercialization of products.

Despite these external drivers, the market is hindered to some extent by the lack of viable manufacturing infrastructure that supports the mass production of quality cell therapy products. Therefore, large-scale manufacturing units for autologous cell therapy and combination therapy products are necessary to meet the market demand. Manufacturers across segments could emulate the sustainable manufacturing models currently used by the market leaders to develop strategic facilities and deploy automated machinery to increase the output.

Nevertheless, the cell therapy market is growing exponentially with technical advancements in various areas. Commercializing late stage hybrid therapy will disrupt the mainstream cellular therapy market. Allogeneic therapy is expected to enjoy significant uptake as the overall market perceptibly shifts from autologous to allogeneic treatments. Market participants are also striving to find treatments for chronic diseases, with close to 50 percent of their pipeline therapy focused on oncology. Evidently, innovative treatments and sustainable manufacturing models are critical for success in this market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Scope and Segmentation
  • Key Questions this Study will Answer
2. Executive Summary
  • Key Takeaways - How is this Market Important to You?
  • Executive Summary - Market Snapshot
  • Key 2016 Predictions - Cell Therapy Market
  • Big Market Themes for Cell Therapy
  • A Vibrant Ecosystem
  • ParadigmShift to Chronic Disease Therapies
  • Regional Highlights and Developments
  • Game-changing Companies
  • Private Investors Pour in Significant Funds
3. Disruptive Pipeline Analysis
  • Key Methodology
  • Next Wave of Cell Therapy
  • Potential Launch Dates
  • Overall Breakdown of Cell Therapy Market
  • Competitive Landscape of Marketed Products*
  • Cell Therapy-Competitive Landscape of Products in Development*
  • Potential Game-changing Therapies
4. Product Dashboard of Leading Commercial Cell Therapy Products
  • Product Dashboard - Apligraf (Organogenesis)
  • Product Dashboard - GINTUIT (Organogenesis)
  • Product Dashboard - Grafix (Osiris Therapeutics)
  • Product Dashboard - Dermagraft (Shire)
  • Product Dashboard - Osteocel Plus (NuVasive)
  • Product Dashboard - ReCell Spray-on Skin (Avita Medical)
  • Product Dashboard - Trinity Evolution (Orthofix)
  • Product Dashboard - BioDfactor (BioD, LLC)
  • Product Dashboard - BioDfence (BioD, LLC)
5. Key Companies and Products to Watch by Indication
  • Competitive Overview of Established Companies
  • Cell Therapy - Cardiovascular
  • Late Stage Product Example - C-Cure (Celyad)
  • Late Stage Product Example - Heartcel (Cell Therapy LTD)
  • Late Stage Product Example - MyoCell (BioHeart)
  • Cell Therapy - Immunology
  • Late Stage Product Example - Prochymal (Mesoblast)
  • Late Stage Product Example - Cx601 (TiGenix)
  • Late Stage Product Example - MPC-100-IV (Remestemcel-L; Mesoblast)
  • Cell Therapy - Oncology
  • Late Stage Product Example - NiCord (Gamida Cell)
  • Late Stage Product Example - StemEx (Gamida Cell)
  • Late Stage Product Example - ImmuniCell (TC BioPharm)
  • Cell Therapy - Musculoskeletal
  • Late Stage Product Example - NeoCart (Histogenics)
  • Late Stage Product Example - NOVOCART 3D (Aesculap/B. Braun)
  • Cell Therapy - Dermatology
  • Late Stage Product Example - ALLO-ASC-DFU (Anterogen)
  • Cell Therapy - Neurology
  • Late Stage Product Example - MPC-06-ID (Mesoblast)
6. Opportunities in Combination Therapies
  • Cell-gene Therapies and How They Work
  • Key Product Example to Watch For - CTL019 (Novartis)
  • Key Product Example to Watch For - JCAR015 (Juno Therapeutics)
  • Key Product Example to Watch For - KTE-C19 (Kite Pharmaceutical)
  • Disruptive Technologies and Advances in this Field
7. Commercialization Analysis
  • Opportunities in this Market
  • Overall Environmental Impact Factors
8. Commercialization Analysis - R&D Considerations
  • Ongoing Stem Cell Clinical Trials by Indication
  • Stem Cell Sources and Stem Cells Used in Pipeline Clinical Trials
  • Commercial Considerations for Selections of Cell Type
9. Commercialization Analysis - Regulatory Considerations
  • Cell Therapy Regulatory Process
  • A Snapshot of Regulatory Policies for Stem Cell Therapy
  • Canada’s Unique Infrastructure - Center of Excellence
  • Japan’s Unique Regulatory Infrastructure
10. Commercializing Analysis-Manufacturing Considerations
  • Autologous versus Allogeneic Cell Products
  • Manufacturing Models that Work - TiGenix
  • Manufacturing Models that Work - Mesoblast
  • Manufacturing Models that Failed - Dendreon Therapeutics
11. Commercialization Analysis - Funding Considerations
  • Funding Key Points
  • Cell Therapy Deals from 2010 to 2015
  • Funding Environment - Where are the Funds Coming From?
  • Merger, Acquisition, and Partnership Assessment
  • Cell Therapy Market - Funding Scenario
12. Conclusion and Take Home Points
  • Key 2016 Predictions - Cell Therapy Market
  • Key Conclusions and Future Outlook
  • Growth Opportunities in Top Segments
  • Pitfalls to Avoid
  • Legal Disclaimer
13. Appendix-Cell Therapy Major Clinical Trial Milestones
  • Cell Therapy Market - Major Ongoing/Recently Completed Clinical Trials
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll